Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

You may be eligible if

• Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening
• HbA1c \>or = 7% and \< or = 10%
• Fasting c-peptide \> or = 1.0 umol
• Body Mass Index \< or = 41 kg/m2
• Mean serum triglycerides \< or = 600 mg/dl